Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05353283 · ClinicalTrials.gov registry record · NA
PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men
A NA study of Risk Reduction, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT05353283: Completed NA study of Risk Reduction, sponsored by University of California, San Francisco.
NCT05353283 is a NA study of Risk Reduction that has completed, run by University of California, San Francisco. The registered enrollment target is 63 participants, below the 3,694-participant average among 13 other Risk Reduction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05353283, a NA study of Risk Reduction, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite advances in HIV prevention, the HIV incidence among young men who have sex with men (YMSM) is increasing, threatening to derail achievement of the United States End the HIV Epidemic goals. Although, pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method, adherence was sufficiently low to comprise efficacy among a high proportion of YMSM in multiple clinical trials and demonstration projects. In this study, the investigators will leverage a novel urine point-of-care drug-level test for PrEP adherence, to both enhance and target motivational-interviewing-based adherence counseling among YMSM, with the goal of preventing HIV infections among this critically at-risk group.
Primary Outcome
Number of participants reporting the intervention to be "somewhat" or "very" acceptable on a five-point Likert scale
Conditions Studied
Interventions
- BEHAVIORAL Motivational Interviewing Counselling
- DEVICE Point-of-care Urine Tenofovir Measurement
Study Locations (1)
California
- University of California, San Francisco/San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2025-07-01 |
| Phase | NA |
What the finished NCT05353283 record still lists
NCT05353283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 3,694-participant average among 13 other Risk Reduction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Risk Reduction appearing as the primary indexed condition, and to 2 interventions - of which Motivational Interviewing Counselling is the first listed.
NCT05353283 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05353283 about?
NCT05353283 is a clinical study titled "PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men". Despite advances in HIV prevention, the HIV incidence among young men who have sex with men (YMSM) is increasing, threatening to derail achievement of the United States End the HIV Epidemic goals. Although, pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method, adherence was su...
What is the current status of trial NCT05353283?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2023-09-01. Estimated completion is 2025-07-01.
What conditions does trial NCT05353283 study?
This clinical trial studies the following conditions: Risk Reduction.
What interventions are being tested in trial NCT05353283?
The interventions under investigation include: Motivational Interviewing Counselling (BEHAVIORAL), Point-of-care Urine Tenofovir Measurement (DEVICE).
Who is sponsoring clinical trial NCT05353283?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05353283 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Risk Reduction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05353283's enrollment target sits among peer trials
63 13th of 13 higher than 1 of 13 other Risk Reduction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Risk Reduction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tennessee Youth Prepared for Success
ACTIVE NOT RECRUITING · NA
-
Efficacy of Communication Modalities for Promoting Flu Shots
COMPLETED · NA
-
Nature and Health: How Does Lifestyle and Environment Affect Health and Wellness
COMPLETED · NA
-
Electronic Confirmed Versus Conventional Consenting Process: A Randomized Controlled Trial
COMPLETED · NA
-
Building Stronger Allies
COMPLETED · NA
-
Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI